
Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) – HC Wainwright boosted their Q4 2026 earnings per share (EPS) estimates for Spero Therapeutics in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.12) for the quarter, up from their previous forecast of ($0.14). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($0.97) per share.
SPRO has been the subject of several other reports. Wall Street Zen cut shares of Spero Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Weiss Ratings upgraded shares of Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, November 10th. Cantor Fitzgerald started coverage on shares of Spero Therapeutics in a research report on Wednesday, October 28th. They set an “overweight” rating and a $6.00 price target on the stock. Compass Point raised shares of Spero Therapeutics to a “neutral” rating in a report on Monday, September 14th. Finally, Zacks Research upgraded shares of Spero Therapeutics to a “hold” rating in a research report on Monday, September 14th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $6.00.
Spero Therapeutics Price Performance
Shares of NASDAQ SPRO opened at $0.90 on Wednesday. The stock has a market capitalization of $52.51 million, a price-to-earnings ratio of 11.83 and a beta of 1.59. The firm’s 50 day simple moving average is $1.13 and its 200-day simple moving average is $1.90. Spero Therapeutics has a 12 month low of $0.88 and a 12 month high of $3.08.
Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.29). Spero Therapeutics had a net margin of 24.90% and a return on equity of 13.98%.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Susquehanna Fundamental Investments LLC purchased a new stake in Spero Therapeutics in the 2nd quarter worth $36,000. Global Retirement Partners LLC acquired a new position in Spero Therapeutics during the second quarter worth $55,000. Empowered Funds LLC purchased a new position in Spero Therapeutics during the third quarter valued at $77,000. Marshall Wace LLP purchased a new position in Spero Therapeutics during the third quarter valued at $236,000. Finally, GSA Capital Partners LLP purchased a new position in Spero Therapeutics during the second quarter valued at $632,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.
Insider Buying and Selling
In other news, insider Esther Rajavelu sold 40,851 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $1.04, for a total value of $42,485.04. Following the completion of the sale, the insider directly owned 946,000 shares in the company, valued at $983,840. The trade was a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.90% of the company’s stock.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious and difficult-to-treat bacterial infections. Its work has centered on antibiotic candidates intended to address infections for which existing treatment options may be limited. The company’s pipeline has included tebipenem HBr, an oral antibiotic candidate studied for complicated urinary tract infections, and programs targeting drug-resistant Gram-negative bacteria and nontuberculous mycobacterial infections.
Featured Stories
- Five stocks we like better than Spero Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
